

Resource Summary Report

Generated by RRID on Aug 12, 2026

Open Targets Platform

RRID:SCR_021702

Type: Tool

Proper Citation

Open Targets Platform (RRID:SCR_021702)

Resource Information

URL: <https://platform.opentargets.org/>

Proper Citation: Open Targets Platform (RRID:SCR_021702)

Description: Platform for supporting systematic drug–target identification and prioritisation. Provides users with queryable knowledgebase and user interface to aid systematic target identification and prioritisation for drug discovery based upon underlying evidence.

Resource Type: data or information resource, service resource

Defining Citation: [DOI:10.1093/nar/gkaa1027](https://doi.org/10.1093/nar/gkaa1027)

Keywords: Evidence based systematic prioritisation, targets for disease treatment, drug–target identification, drug discovery

Availability: Free, Freely available

Resource Name: Open Targets Platform

Resource ID: SCR_021702

Alternate URLs: <https://www.targetvalidation.org/>

Record Creation Time: 20220129T080357+0000

Record Last Update: 20260808T190218+0000

Ratings and Alerts

No rating or validation information has been found for Open Targets Platform.

No alerts have been found for Open Targets Platform.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 173 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Wei S, et al. (2026) KG-bench: benchmarking graph neural network algorithms for drug repurposing. *Bioinformatics* (Oxford, England), 42(5).

Preziosa P, et al. (2026) Spatial gene expression and functional network abnormalities in multiple sclerosis: exploring biological influence on brain functional reorganization. *Translational psychiatry*, 16(1).

Prakash O, et al. (2026) A network-driven computational framework for identifying FDA-approved drug repurposing across heterogeneous brain cancers. *Frontiers in molecular biosciences*, 13, 1768081.

Zhang Q, et al. (2026) Genome-wide investigation highlights global and local pleiotropy linking neurodevelopmental disorders to acquired hearing problems. *Psychological medicine*, 56, e32.

Reales G, et al. (2026) Design and interpretation of eQTL-GWAS colocalisation studies: Lessons from a large-scale evaluation. *PLoS genetics*, 22(5), e1012141.

Zhang H, et al. (2026) Single-cell transcriptome-wide Mendelian randomization during CD4+ T cell activation reveals immune-mediated mechanisms and drug targets for neuropsychiatric disorders. *Communications biology*, 9(1).

Li H, et al. (2026) Identification of Treatment Targets in Allergic Conjunctivitis Through Proteome-Scale Mendelian Randomization Analysis. *Mediators of inflammation*, 2026, 6432686.

Fu S, et al. (2026) IRF7 is a novel prognostic biomarker in kidney renal clear cell carcinoma. *Scientific reports*, 16(1), 5523.

Scartozzi AC, et al. (2026) Genome-wide investigation of prosody perception: Shared genetic influences between speech rhythm, musical rhythm, and reading traits. *HGG advances*, 7(3), 100581.

Tsepilov YA, et al. (2026) The Human Pleiotropic Map of GWAS Associations and Therapeutic Implications. *bioRxiv : the preprint server for biology*.

Zhang X, et al. (2026) Single-Cell Transcriptome-Wide Mendelian Randomization and Colocalization Uncover Potential Immunocytes-Related Therapeutic Targets for Obesity. *Journal of cellular and molecular medicine*, 30(9), e71185.

Al-Damook N, et al. (2026) Mapping metabolic reprogramming in lung and breast cancer through integrative bioinformatics. *PloS one*, 21(6), e0350628.

Lin M, et al. (2026) Network pharmacology and molecular dynamics simulations reveal shared mechanisms and myopia-specific targets of atropine in myopia and dry eye disease. *Eye and vision (London, England)*, 13(1).

Mei H, et al. (2026) IL3RA identified as novel biomarker and therapeutic target for ER+ breast cancer through plasma proteome-wide mendelian randomization and TCGA database analysis. *Clinical proteomics*, 23(1).

Shaukat M, et al. (2026) Heritable pulmonary arterial hypertension: new genetic findings and environmental triggers. *Scientific reports*, 16(1), 4121.

Xu J, et al. (2026) Large-Scaled Proteomics Analysis for Glaucoma: Integrated Genetics, Multi-Omics, UK Biobank and Therapeutic Analysis. *Investigative ophthalmology & visual science*, 67(2), 4.

Kramarenko DR, et al. (2026) Leveraging the shared and opposing genetic mechanisms in the heritable cardiomyopathies. *Research square*.

Ma X, et al. (2026) Coptidis Rhizoma Alkaloids Alleviate Acetaminophen-Induced Liver Injury by Regulating GSH Metabolism and the TNF Signaling Pathway. *Antioxidants (Basel, Switzerland)*, 15(2).

Zeng D, et al. (2026) Cell type-stratified immunogenetic framework reveals immune drivers and therapeutic targets in kidney stone disease. *Molecular therapy. Nucleic acids*, 37(2), 102964.

Laman Trip DS, et al. (2026) A tissue-specific atlas of protein-protein associations enables prioritization of candidate disease genes. *Nature biotechnology*, 44(4), 654.